Sign In
Buy DVAX
$15.50
+0 (+0%)
At Close: May 08, 2026
Dynavax Reports Third Quarter 2024 Financial Results and Provides Business Updates
04:02pm, Thursday, 07'th Nov 2024
HEPLISAV-B ® quarterly net product revenue of $79.3 million, representing 27% year-over-year growth Hepatitis B adult vaccine market expected to expand to a peak of over $900 million by 2030, with HE
Dynavax Announces $200 Million Share Repurchase Program
04:01pm, Thursday, 07'th Nov 2024
EMERYVILLE, Calif. , Nov. 7, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, tod
Glancy Prongay & Murray LLP Announces Investigation of Dynavax Technologies Corporation (DVAX)
01:10pm, Wednesday, 06'th Nov 2024
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Dynavax Technologies Corporation (Nasdaq: DVAX) concerning the Company and its directors' and officers
Dynavax Adopts Limited-Duration Stockholder Rights Plan
08:30am, Tuesday, 29'th Oct 2024
EMERYVILLE, Calif. , Oct. 29, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines,
Dynavax to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024
04:10pm, Thursday, 24'th Oct 2024
EMERYVILLE, Calif. , Oct. 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, wil
3 'Repeatable' Biotech Trades
12:46pm, Wednesday, 25'th Sep 2024
Small-cap biotech stocks have struggled over the past five years, but lower interest rates may boost sentiment and M&A activity, benefiting the sector. One way I have kept my biotech portfolio churnin
Dynavax Technologies: A Two Trick Pony Operating With A Single Trick
04:32am, Friday, 23'rd Aug 2024
Dynavax has experienced fluctuations in stock performance since the author's initial coverage. HEPLISAV-B is Dynavax's primary revenue source for the foreseeable future, with CpG-1018 currently sideli
How Much Upside is Left in Dynavax Technologies (DVAX)? Wall Street Analysts Think 135.98%
10:55am, Friday, 09'th Aug 2024
The mean of analysts' price targets for Dynavax Technologies (DVAX) points to a 136% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am
Dynavax Technologies Corporation (DVAX) Q2 2024 Earnings Call Transcript
08:54pm, Tuesday, 06'th Aug 2024
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Paul Cox - VP, Investor Relations & Corporate Communications Ryan Spence
Dynavax Technologies (DVAX) Tops Q2 Earnings Estimates
08:10pm, Tuesday, 06'th Aug 2024
Dynavax Technologies (DVAX) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.03 per share a year ago.
Dynavax Reports Second Quarter 2024 Financial Results and Provides Business Updates
04:01pm, Tuesday, 06'th Aug 2024
Achieved record quarterly HEPLISAV-B ® net product revenue of $70.2 million, growing 24% year-over-year Reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 million Initi
Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
04:00pm, Tuesday, 23'rd Jul 2024
EMERYVILLE, Calif. , July 23, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, wil
New Strong Sell Stocks for July 9th
08:26am, Tuesday, 09'th Jul 2024
BMWYY, DXC and DVAX have been added to the Zacks Rank #5 (Strong Sell) List on July 9, 2024.
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program
04:09pm, Thursday, 27'th Jun 2024
EMERYVILLE, Calif. , June 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, to
Dynavax to Present at Upcoming Investor Conferences
04:18pm, Tuesday, 28'th May 2024
EMERYVILLE, Calif. , May 28, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, t
